A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules
8 de maio de 2020 atualizado por: The First Affiliated Hospital with Nanjing Medical University
Gastrointestinal Stromal Tumors (GIST) is the most common mesenchymal tumor of the gastrointestinal tract, and the incidence rate in China has increased year by year in recent years.Gastrointestinal stromal tumors are not sensitive to radiotherapy and traditional infusion chemotherapy.
Currently, they are generally treated with surgery, but they are prone to recurrence and metastasis.For nodules with a particle size between 2 and 5 cm, there may be both benign and malignant, and there is still a lack of fast and accurate methods for distinguishing benign and malignant.Many benign nodules were removed (in the pathological examination of postoperative resected tissue).
In addition, if it is found to be late, there is a possibility of invading surrounding tissues and metastasis, so that it is impossible to cure.
Therefore, early diagnosis and early surgery and benign and malignant differentiation of small nodules are the key to the clinical diagnosis and treatment of gastrointestinal stromal tumors.At present, second-generation gene sequencing (NGS) and liquid biopsy are rarely reported in the field of GIST.
A few domestic and foreign studies have found that it can detect rare mutation types, and may find secondary gene mutations early, which has potential applicability, but Overall, the clinical guidance of these NGS-based studies focuses on prognosis and drug resistance , as well as some studies based on low-throughput platforms.
Therefore, early diagnosis and benign and malignant discrimination based on high-throughput sequencing and liquid biopsy have significant clinical significance for the diagnosis and treatment of gastrointestinal stromal tumors.
Visão geral do estudo
Status
Desconhecido
Condições
Intervenção / Tratamento
- Outro: DNA extraction of tumer tissue samples and high-throughput sequencing of small panels
- Outro: DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels
- Outro: DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels
Tipo de estudo
Observacional
Inscrição (Antecipado)
300
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recrutamento
- First Affiliated Hospital of Nanjing Medical University
-
Contato:
- Xiqiao none Zhou, doctor
- Número de telefone: 13951826318
- E-mail: Xiqiao_zhou@126.com
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Método de amostragem
Amostra de Probabilidade
População do estudo
Gastrointestinal stromal tumor patients in Jiangsu Provincial People's Hospital
Descrição
Inclusion Criteria:
- Patients who are scheduled for stromal tumor resection
- Signed informed consent
Exclusion Criteria:
- the vital signs are not stable
- unconscious
- unwilling to cooperate
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
The construction of Gene detection technology flow
At this stage, a small panel targeted high-throughput sequencing process for gastrointestinal stromal tumors was established, and the association of tumor-associated mutation profiles in different patients with clinical stage was initially explored.
It is planned to collect about 100 cases of gastrointestinal stromal tumors after surgery (freezing tissue or FFPE sections), DNA extraction and high-throughput sequencing of small panels, and analysis of the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging).
|
DNA extraction of stromal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed
|
|
Establishment of non-invasive gene testing technology process
In this stage, we plan to establish a small panel of peripheral blood cfDNA targeting high-throughput sequencing process, and verify the consistency of peripheral blood cfDNA and tissue gDNA in gene detection of gastrointestinal stromal tumors.
About 50 patients were planned to be enrolled.
Peripheral blood was collected once for each patient and the blood volume was 10mL.
Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion .
DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor.
|
DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor
DNA extraction and small panel sequencing were conducted for each patient sample.
Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients
|
|
Prospective cohort (double-blind recommended)
Peripheral blood of about 150 patients was collected once and the blood volume was 10mL .
Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion.
Patients focus on the early stage of stromal tumors or those whose size under gastroenteroscopy is between 2 and 5 cm.
DNA extraction and small panel sequencing were conducted for each patient sample.
Based on the indicator results of the previous mutation spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutation spectrum, and compared with the real clinical data of patients.
|
DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor
DNA extraction and small panel sequencing were conducted for each patient sample.
Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Genetic mutations of patients with stromal tumor assessed by next-generation sequencing
Prazo: 2019.8-2019.10
|
DNA extraction of tumer tissue samples ,Preliminary exploration of tumor related mutation spectrum in different patients by gene sequencing
|
2019.8-2019.10
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Genetic mutations of patients with stromal tumor assessed by next-generation sequencing
Prazo: 2019.11-2020.5
|
DNA extraction of tumer tissue samples and blood tissue .To evaluate the consistency of peripheral blood cfDNA and tissue gDNA in gene detection of gastrointestinal stromal tumors,Using mutational spectra to determine the clinical stage of the patient and the benign and malignant small nodules
|
2019.11-2020.5
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Colaboradores
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de setembro de 2019
Conclusão Primária (Antecipado)
31 de maio de 2020
Conclusão do estudo (Antecipado)
31 de maio de 2020
Datas de inscrição no estudo
Enviado pela primeira vez
18 de outubro de 2019
Enviado pela primeira vez que atendeu aos critérios de CQ
27 de outubro de 2019
Primeira postagem (Real)
29 de outubro de 2019
Atualizações de registro de estudo
Última Atualização Postada (Real)
11 de maio de 2020
Última atualização enviada que atendeu aos critérios de controle de qualidade
8 de maio de 2020
Última verificação
1 de maio de 2020
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2019-SR-358
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .